Genitourinary tumour therapy developer Asieris Pharmaceuticals has closed a Series D round of financing raising over 700 million yuan ($106 million) led by Chinese global venture capital firm Qiming Venture Partners, according to a company statement on Wednesday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
